Institution
Paul Sabatier University
Education•Toulouse, France•
About: Paul Sabatier University is a education organization based out in Toulouse, France. It is known for research contribution in the topics: Population & Catalysis. The organization has 15431 authors who have published 23386 publications receiving 858364 citations.
Topics: Population, Catalysis, Context (language use), Adipose tissue, Electron
Papers published on a yearly basis
Papers
More filters
••
TL;DR: It is concluded that automated shape analysis generates sensitive measurements of early neurodegeneration which predates the onset of dementia and thus provides a prognostic biomarker for conversion of MCI to AD.
205 citations
•
17 Jan 1997TL;DR: Partial table of contents: CLARIFYING INFORMATION: SENSING and ENHANCING and EXPLOITING INFORMATION: DESIGNING and OPTIMIZING.
Abstract: Partial table of contents: CLARIFYING INFORMATION: SENSING AND ENHANCING. Elicitation, Pooling, and Assessment of Expert Opinion in the Possibilistic Framework (S. Sandri). CLARIFYING INFORMATION: ABSTRACTING AND MODELING. Learning from Imperfect Data (B. Bouchon-Meunier, et al.). RETRIEVING INFORMATION: QUERYING. Extending SQL Retrieval Features for the Handling of Flexible Queries (P. Bosc & O. Pivert). A Fuzzy SQL Summary Language for Data Discovery (D. Rasmussen & R. Yager). RETRIEVING INFORMATION: REASONING. Fuzzy Set Methods in Inheritance Networks (R. Yager). EXPLOITING INFORMATION: DECISION-MAKING. Operators in Models of Decision Making (H. Zimmermann). Risk Management with Imprecise Information (K. Engermann, et al.). EXPLOITING INFORMATION: DESIGNING AND OPTIMIZING. Fuzzy Scheduling: Principles and Experiments (H. Fargier). Index.
205 citations
••
TL;DR: The results indicate that PhoP coordinately and positively regulates the synthesis of methyl-branched fatty acid-containing acyltrehaloses known to be restricted to pathogenic species of the M. tuberculosis complex, namely diacylt rehaloses, polyacyltre Haloses, and sulfolipids.
205 citations
••
TL;DR: Treatment with vismodegib adds a novel therapeutic modality from which patients with advanced basal cell carcinoma can benefit substantially and is designed to assess the safety of vismODEgib in a situation similar to routine practice, with a long follow-up.
Abstract: Summary Background The Hedgehog pathway inhibitor vismodegib has shown clinical benefit in patients with advanced basal cell carcinoma and is approved for treatment of patients with advanced basal cell carcinoma for whom surgery is inappropriate. STEVIE was designed to assess the safety of vismodegib in a situation similar to routine practice, with a long follow-up. Methods In this multicentre, open-label trial, adult patients with histologically confirmed locally advanced basal cell carcinoma or metastatic basal cell carcinoma were recruited from regional referral centres or specialist clinics. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, and adequate organ function. Patients with locally advanced basal cell carcinoma had to have been deemed ineligible for surgery. All patients received 150 mg oral vismodegib capsules once a day on a continuous basis in 28-day cycles. The primary objective was safety (incidence of adverse events until disease progression or unacceptable toxic effects), with assessments on day 1 of each treatment cycle (28 days) by principal investigator and coinvestigators at the site. Efficacy variables were assessed as secondary endpoints. The safety evaluable population included all patients who received at least one dose of study drug. Patients with histologically confirmed basal cell carcinoma who received at least one dose of study drug were included in the efficacy analysis. An interim analysis was pre-planned after 500 patients achieved 1 year of follow-up. This trial is registered with ClinicalTrials.gov, number NCT01367665. The study is still ongoing. Findings Between June 30, 2011, and Nov 6, 2014, we enrolled 1227 patients. At clinical cutoff (Nov 6, 2013), 499 patients (468 with locally advanced basal cell carcinoma and 31 with metastatic basal cell carcinoma) had received study drug and had the potential to be followed up for 12 months or longer. Treatment was discontinued in 400 (80%) patients; 180 (36%) had adverse events, 70 (14%) had progressive disease, and 51 (10%) requested to stop treatment. Median duration of vismodegib exposure was 36·4 weeks (IQR 17·7–62·0). Adverse events happened in 491 (98%) patients; the most common were muscle spasms (317 [64%]), alopecia (307 [62%]), dysgeusia (269 [54%]), weight loss (162 [33%]), asthenia (141 [28%]), decreased appetite (126 [25%]), ageusia (112 [22%]), diarrhoea (83 [17%]), nausea (80 [16%]), and fatigue (80 [16%]). Most adverse events were grade 1 or 2. We recorded serious adverse events in 108 (22%) of 499 patients. Of the 31 patients who died, 21 were the result of adverse events. As assessed by investigators, 302 (66·7%, 62·1–71·0) of 453 patients with locally advanced basal cell carcinoma had an overall response (153 complete responses and 149 partial responses); 11 (37·9%; 20·7–57·7) of 29 patients with metastatic basal cell carcinoma had an overall response (two complete responses, nine partial responses). Interpretation This study assessed the use of vismodegib in a setting representative of routine clinical practice for patients with advanced basal cell carcinoma. Our results show that treatment with vismodegib adds a novel therapeutic modality from which patients with advanced basal cell carcinoma can benefit substantially. Funding F Hoffmann-La Roche.
204 citations
••
TL;DR: The use of this inclusive and sequential Tn numbering system for transposable elements, as described here, recognizes the ease of interspecies spread of individual elements, and allows for the naming of mosaic elements containing segments from two or more previously described types of transposons or plasmids.
204 citations
Authors
Showing all 15486 results
Name | H-index | Papers | Citations |
---|---|---|---|
Yury Gogotsi | 171 | 956 | 144520 |
Tobin J. Marks | 159 | 1621 | 111604 |
L. Montier | 138 | 403 | 97094 |
Jean-Paul Kneib | 138 | 805 | 89287 |
Olivier Forni | 137 | 548 | 95819 |
J. Aumont | 131 | 299 | 95006 |
Julian I. Schroeder | 120 | 315 | 50323 |
Bruno Vellas | 118 | 1011 | 70667 |
Christopher G. Goetz | 116 | 651 | 59510 |
Didier Dubois | 113 | 742 | 54741 |
Alain Dufresne | 111 | 358 | 45904 |
Henri Prade | 108 | 917 | 54583 |
Louis Bernatchez | 106 | 568 | 35682 |
Walter Wahli | 105 | 365 | 49372 |
Patrice D. Cani | 100 | 370 | 49523 |